Abstract
Individuals with mutations in breast cancer susceptibility genes BRCA1 and BRCA2 have up to an 80% risk of developing breast cancer by the age of 70. Sequencing-based genetic tests are now available to identify mutation carriers in an effort to reduce mortality through prevention and early diagnosis. However, lack of a suitable functional assay hinders the risk assessment of more than 1,900 BRCA1 and BRCA2 variants in the Breast Cancer Information Core database that do not clearly disrupt the gene product. We have established a simple, versatile and reliable assay to test for the functional significance of mutations in BRCA2 using mouse embryonic stem cells (ES cells) and bacterial artificial chromosomes and have used it to classify 17 sequence variants. The assay is based on the ability of human BRCA2 to complement the loss of endogenous Brca2 in mouse ES cells. This technique may also serve as a paradigm for functional analysis of mutations found in other genes linked to human diseases.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
BRCA2-DSS1 interaction is dispensable for RAD51 recruitment at replication-induced and meiotic DNA double strand breaks
Nature Communications Open Access 01 April 2022
-
A complex of BRCA2 and PP2A-B56 is required for DNA repair by homologous recombination
Nature Communications Open Access 30 September 2021
-
A computational model for classification of BRCA2 variants using mouse embryonic stem cell-based functional assays
npj Genomic Medicine Open Access 08 December 2020
Access options
Subscribe to Journal
Get full journal access for 1 year
$79.00
only $6.58 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Buy article
Get time limited or full article access on ReadCube.
$32.00
All prices are NET prices.




Accession codes
Change history
11 July 2008
In the version of this article initially published online, the online publication date was listed in correctly as 6 July 2007 on the PDF. The error has been corrected for all versions of this article.
References
Thompson, D., Easton, D.F. & Goldgar, D.E. A full-likelihood method for the evaluation of causality of sequence variants from family data. Am. J. Hum. Genet. 73, 652–655 (2003).
Carvalho, M.A., Couch, F.J. & Monteiro, A.N. Functional assays for BRCA1 and BRCA2. Int. J. Biochem. Cell Biol. 39, 298–310 (2007).
Sharan, S.K. et al. Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2. Nature 386, 804–810 (1997).
Ramirez-Solis, R., Liu, P. & Bradley, A. Chromosome engineering in mice. Nature 378, 720–724 (1995).
Oddoux, C. et al. The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%. Nat. Genet. 14, 188–190 (1996).
Freedman, M.L. et al. Common variation in BRCA2 and breast cancer risk: a haplotype-based analysis in the Multiethnic Cohort. Hum. Mol. Genet. 13, 2431–2441 (2004).
Wu, K. et al. functional evaluation and cancer risk assessment of brca2 unclassified variants. Cancer Res. 65, 417–426 (2005).
Szabo, C., Masiello, A., Ryan, J.F. & Brody, L.C. The breast cancer information core: database design, structure, and scope. Hum. Mutat. 16, 123–131 (2000).
Wong, J.M., Ionescu, D. & Ingles, C.J. Interaction between BRCA2 and replication protein A is compromised by a cancer-predisposing mutation in BRCA2. Oncogene 22, 28–33 (2003).
Goldgar, D.E. et al. Integrated evaluation of DNA sequence variants of unknown clinical significance: application to BRCA1 and BRCA2. Am. J. Hum. Genet. 75, 535–544 (2004).
Easton, D.F. et al. A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes. Am. J. Hum. Genet. 81, 873–883 (2007).
Atanassov, B.S., Barrett, J.C. & Davis, B.J. Homozygous germ line mutation in exon 27 of murine Brca2 disrupts the Fancd2-Brca2 pathway in the homologous recombination-mediated DNA interstrand cross-links' repair but does not affect meiosis. Genes Chromosom. Cancer 44, 429–437 (2005).
Donoho, G. et al. Deletion of Brca2 exon 27 causes hypersensitivity to DNA crosslinks, chromosomal instability and reduced life span in mice. Genes Chromosom. Cancer 36, 317–331 (2003).
Mazoyer, S. et al. A polymorphic stop codon in BRCA2. Nat. Genet. 14, 253–254 (1996).
Marple, T., Kim, T.M. & Hasty, P. Embryonic stem cells deficient for Brca2 or Blm exhibit divergent genotoxic profiles that support opposing activities during homologous recombination. Mutat. Res. 602, 110–120 (2006).
Godthelp, B.C. et al. Cellular characterization of cells from the Fanconi anemia complementation group, FA-D1/BRCA2. Mutat. Res. 601, 191–201 (2006).
Patel, K.J. et al. Involvement of Brca2 in DNA repair. Mol. Cell 1, 347–357 (1998).
Morimatsu, M., Donoho, G. & Hasty, P. Cells deleted for Brca2 COOH terminus exhibit hypersensitivity to γ-radiation and premature senescence. Cancer Res. 58, 3441–3447 (1998).
Yuan, S.-S.F. et al. BRCA2 is required for ionizing radiation–induced assembly of Rad51 complex in vivo. Cancer Res. 59, 3547–3551 (1999).
Khanna, K.K. & Jackson, S.P. DNA double-strand breaks: signaling, repair and the cancer connection. Nat. Genet. 27, 247–254 (2001).
Yang, Y., Swaminathan, S., Martin, B.K. & Sharan, S.K. Aberrant splicing induced by missense mutations in BRCA1: clues from a humanized mouse model. Hum. Mol. Genet. 12, 2121–2131 (2003).
Fackenthal, J.D., Cartegni, L., Krainer, A.R. & Olopade, O.I. BRCA2 T2722R is a deleterious allele that causes exon skipping. Am. J. Hum. Genet. 71, 625–631 (2002).
Yang, H. et al. BRCA2 function in DNA binding and recombination from a BRCA2–DSS1-ssDNA structure. Science 297, 1837–1848 (2002).
Deffenbaugh, A.M., Frank, T.S., Hoffman, M., Cannon-Albright, L. & Neuhausen, S.L. Characterization of common BRCA1 and BRCA2 variants. Genet. Test. 6, 119–121 (2002).
Sharan, S.K. et al. BRCA2 deficiency in mice leads to meiotic impairment and infertility. Development 131, 131–142 (2004).
Court, D.L. et al. Mini-lambda: a tractable system for chromosome and BAC engineering. Gene 315, 63–69 (2003).
Yang, Y. & Sharan, S.K. A simple two-step, 'hit and fix' method to generate subtle mutations in BACs using short denatured PCR fragments. Nucleic Acids Res. 31, e80 (2003).
Scudiero, D.A. et al. Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res. 48, 4827–4833 (1988).
Kuznetsov, S. et al. RAD51C deficiency in mice results in early prophase I arrest in males and sister chromatid separation at metaphase II in females. J. Cell Biol. 176, 581–592 (2007).
Acknowledgements
We thank J. Acharya, K. Biswas, S. Chang, I. Daar, G. Merlino, A. Nussenzweig, S. Philip and L. Tessarollo for helpful discussions and critical review of the manuscript. We also thank A. Deffenbaugh for providing epidemiological data; B. Martin, S. Burkett, L. North and S. Stauffer for technical assistance; L. Cleveland for help with DNA sequencing; R. Frederickson and A. Kane for illustrations; D. Du (US National Cancer Institute–Frederick) for the Rosa26 genomic construct; K. Biswas (US National Cancer Institute–Frederick) for the Brca1 targeting construct; S. West (Cancer Research UK) for RAD51 antibody; and M. Lewandoski for helpful discussions. We thank C. Ware (University of Washington, Seattle) for providing human ES cell pellet and J. Collins for help with computer modeling. The research was sponsored by the Center for Cancer Research, National Cancer Institute, US National Institutes of Health.
Author information
Authors and Affiliations
Contributions
S.G.K. conducted all of the experiments and wrote the manuscript. P.L. helped with initial concept and generated selection marker cassettes. S.K.S. conceived the idea, generated the conditional ES cell line, supervised the study and wrote the manuscript.
Corresponding author
Supplementary information
Supplementary Text and Figures
Supplementary Figs. 1–6 and Supplementary Table 1 (PDF 581 kb)
Rights and permissions
About this article
Cite this article
Kuznetsov, S., Liu, P. & Sharan, S. Mouse embryonic stem cell–based functional assay to evaluate mutations in BRCA2. Nat Med 14, 875–881 (2008). https://doi.org/10.1038/nm.1719
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm.1719
This article is cited by
-
BRCA2-DSS1 interaction is dispensable for RAD51 recruitment at replication-induced and meiotic DNA double strand breaks
Nature Communications (2022)
-
A complex of BRCA2 and PP2A-B56 is required for DNA repair by homologous recombination
Nature Communications (2021)
-
Functional evaluation of five BRCA2 unclassified variants identified in a Sri Lankan cohort with inherited cancer syndromes using a mouse embryonic stem cell-based assay
Breast Cancer Research (2020)
-
Variants of uncertain significance in the era of high-throughput genome sequencing: a lesson from breast and ovary cancers
Journal of Experimental & Clinical Cancer Research (2020)
-
A computational model for classification of BRCA2 variants using mouse embryonic stem cell-based functional assays
npj Genomic Medicine (2020)